International Nonproprietary Names for Pharmaceutical Substances (INN)

RECOMMENDED International Nonproprietary Names: List 56

Notice is hereby given that, in accordance with paragraph 7 of the Procedure for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances [*Off. Rec. Wld Health Org.*, 1955, **60**, 3 (Resolution EB15.R7); 1969, **173**, 10 (Resolution EB43.R9)], the following names are selected as Recommended International Nonproprietary Names. The inclusion of a name in the lists of Recommended International Nonproprietary Names does not imply any recommendation of the use of the substance in medicine or pharmacy.
Lists of Proposed (1–91) and Recommended (1–52) International Nonproprietary Names can be found in *Cumulative List No. 11, 2004* (available in CD-ROM only).

Dénominations communes internationales des Substances pharmaceutiques (DCI)

Dénominations communes internationales RECOMMANDÉES: Liste 56

Il est notifié que, conformément aux dispositions du paragraphe 7 de la Procédure à suivre en vue du choix de Dénominations communes internationales recommandées pour les Substances pharmaceutiques [*Actes off. Org. mond. Santé*, 1955, **60**, 3 (résolution EB15.R7); 1969, **173**, 10 (résolution EB43.R9)] les dénominations ci-dessous sont choisies par l'Organisation mondiale de la Santé en tant que dénominations communes internationales recommandées. L'inclusion d'une dénomination dans les listes de DCI recommandées n'implique aucune recommandation en vue de l'utilisation de la substance correspondante en médecine ou en pharmacie.
On trouvera d'autres listes de Dénominations communes internationales proposées (1–91) et recommandées (1–52) dans la *Liste récapitulative No. 11, 2004* (disponible sur CD-ROM seulement).

Denominaciones Comunes Internacionales para las Sustancias Farmacéuticas (DCI)

Denominaciones Comunes Internacionales RECOMENDADAS: Lista 56

De conformidad con lo que dispone el párrafo 7 del Procedimiento de Selección de Denominaciones Comunes Internacionales Recomendadas para las Sustancias Farmacéuticas [*Act. Of. Mund. Salud*, 1955, **60**, 3 (Resolución EB15.R7); 1969, **173**, 10 (Resolución EB43.R9)], se comunica por el presente anuncio que las denominaciones que a continuación se expresan han sido seleccionadas como Denominaciones Comunes Internacionales Recomendadas. La inclusión de una denominación en las listas de las Denominaciones Comunes Recomendadas no supone recomendación alguna en favor del empleo de la sustancia respectiva en medicina o en farmacia.
Las listas de Denominaciones Comunes Internacionales Propuestas (1–91) y Recomendadas (1–52) se encuentran reunidas en *Cumulative List No. 11, 2004* (disponible sólo en CD-ROM).

Latin, English, French, Spanish: *Recommended INN*	*Chemical name or description; Molecular formula; Graphic formula*
DCI Recommandée	*Nom chimique ou description; Formule brute; Formule développée*
DCI Recomendada	*Nombre químico o descripción; Fórmula molecular; Fórmula desarrollada*

alcaftadinum

alcaftadine	11-(1-methylpiperidin-4-ylidene)-6,11-dihydro-5*H*-imidazo=[2,1-*b*][3]benzazepine-3-carbaldehyde
alcaftadine	11-(1-méthylpipéridin-4-ylidène)-6,11-dihydro-5*H*-imidazo=[2,1-*b*][3]benzazépine-3-carbaldéhyde
alcaftadina	11-(1-metilpiperidin-4-ilideno)-6,11-dihidro-5*H*-imidazo=[2,1-*b*][3]benzazepina-3-carbaldehído

$C_{19}H_{21}N_3O$



amibegronum

amibegron	ethyl {[(7*S*)-7-{[(2*R*)-2-(3-chlorophenyl)-2-hydroxyethyl]amino}-5,6,7,8-tetrahydronaphthalen-2-yl]oxy}acetate
amibégron	[[(7*S*)-7-[[(2*R*)-2-(3-chlorophényl)-2-hydroxyéthyl]amino]-5,6,7,8-tétrahydronaphtalén-2-yl]oxy]acétate d'éthyle
amibegrón	[[(7*S*)-7-[[(2*R*)-2-(3-clorofenil)-2-hidroxietil]amino]-5,6,7,8-tetrahidronaftalen-2-il]oxi]acetato de etilo

$C_{22}H_{26}ClNO_4$



antithrombinum alfa

antithrombin alfa — human antithrombin-III from the milk of transgenic goats (glycoform alfa)

antithrombine alfa — antithrombine-III humaine extraite du lait de chèvre transgénique (glycoforme alfa)

antitrombina alfa — antitrombina-III humana extraida de la leche de cabra transgénica (glicoforma alfa)

$C_{2191}H_{3451}N_{583}O_{656}S_{18}$

HGSPVDICTA KPRDIPMNPM CIYRSPEKKA TEDEGSEQKI
PEATNRRVWE LSKANSRFAT TFYQHLADSK NDNDNIFLSP
LSISTAFAMT KLGAC*NDTLQ QLMEVFKFDT ISEKTSDQIH
FFFAKLNCRL YRKA*NKSSKL VSANRLFGDK SLTF*NETYQD
ISELVYGAKL QPLDFKENAE QSRAAINKWV S*NKTEGRITD
VIPSEAINEL TVLVLVNTIY FKGLWKSKFS PENTRKELFY
KADGESCSAS MMYQEGKFRY RRVAEGTQVL ELPFKGDDIT
MVLILPKPEK SLAKVEKELT PEVLQEWLDE LEEMMLVVHM
PRFRIEDGFS LKEQLQDMGL VDLFSPEKSK LPGIVAEGRD
DLYVSDAFHK AFLEVNEEGS EAAASTAVVI AGRSLNPNRV
TFKANRPFLV FIREVPLNTI IFMGRVANPC VK

* glycosylation sites
* sites de glycosylation
* posiciónes de glicosilación

apadenosonum

apadenoson — methyl *trans*-4-{3-[6-amino-9-(*N*-ethyl-β-D-ribofuranosyluronamide)-9*H*-purin-2-yl]prop-2-ynyl}cyclohexanecarboxylate

apadénoson — *trans*-4-[3-[6-amino-9-(*N*-éthyl-β-D-ribofuranosyluronamide)-9*H*-purin-2-yl]prop-2-ynyl]cyclohexanecarboxylate de méthyle

apadenosón — *trans*-4-[3-[6-amino-9-(*N*-etil-β-D-ribofuranosiluronamida)-9*H*-purin-2-il]prop-2-inil]ciclohexanocarboxilato de metilo

$C_{23}H_{30}N_6O_6$



aplavirocum

aplaviroc — 4-(4-{[(3*R*)-1-butyl-3-[(*R*)-cyclohexylhydroxymethyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undecan-9-yl]methyl}phenoxy)benzoic acid

aplaviroc — acide 4-[4-[[(3*R*)-1-butyl-3-[(*R*)-cyclohexylhydroxyméthyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undéc-9-yl]méthyl]phénoxy]benzoïque

aplaviroc — ácido 4-[4-[[(3*R*)-1-butil-3-[(*R*)-ciclohexilhidroximetil]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-il]metil]fenoxi]benzoico

$C_{33}H_{43}N_3O_6$



avosentanum

avosentan — *N*-[6-methoxy-5-(2-methoxyphenoxy)-2-(pyridin-4-yl)pyrimidin-4-yl]-5-methylpyridine-2-sulfonamide

avosentan — *N*-[6-méthoxy-5-(2-méthoxyphénoxy)-2-(pyridin-4-yl)pyrimidin-4-yl]-5-méthylpyridine-2-sulfonamide

avosentán — 5-metil-*N*-[6-metoxi-5-(2-metoxifenoxi)-2-(piridin-4-il)pirimidin-4-il]piridina-2-sulfonamida

$C_{23}H_{21}N_5O_5S$



axitinibum

axitinib — *N*-methyl-2-({3-[(1*E*)-2-(pyridin-2-yl)ethenyl]-1*H*-indazol-6-yl}sulfanyl)benzamide

axitinib — *N*-méthyl-2-[[3-[(1*E*)-2-(pyridin-2-yl)éthényl]-1*H*-indazol-6-yl]sulfanyl]benzamide

axitinib — *N*-metil-2-[[3-[(1*E*)-2-(piridin-2-il)etenil]-1*H*-indazol-6-il]=sulfanil]benzamida

$C_{22}H_{18}N_4OS$



bosutinibum
bosutinib — 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile

bosutinib — 4-[(2,4-dichloro-5-méthoxyphényl)amino]-6-méthoxy-7-[3-(4-méthylpipérazin-1-yl)propoxy]quinoléine-3-carbonitrile

bosutinib — 4-[(2,4-dicloro-5-metoxifenil)amino]-6-metoxi-7-[3-(4-metilpiperazin-1-il)propoxi]quinolina-3-carbonitrilo

$C_{26}H_{29}Cl_2N_5O_3$



brecanavirum
brecanavir — (3*R*,3a*S*,6a*R*)-hexahydrofurano[2,3-*b*]furan-3-yl [(2*S*,3*R*)-4-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-3-hydroxy-1-{4-[(2-methyl-1,3-thiazol-4-yl)methoxy]phenyl}butan-2-yl]carbamate

brécanavir — [(1*S*,2*R*)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-méthylpropyl)amino]-2-hydroxy-1-[4-[(2-méthylthiazol-4-yl)méthoxy]benzyl]= propyl]carbamate de (3*R*,3a*S*,6a*R*)-hexahydrofuro[2,3-*b*]furan-3-yle

brecanavir — [(1*S*,2*R*)-3-[(1,3-benzodioxol-5-ilsulfonil)(2-metilpropil)amino]-2-hidroxi-1-[4-[(2-metiltiazol-4-il)metoxi]bencil]propil]carbamato de (3*R*,3a*S*,6a*R*)-hexahidrofuro[2,3-*b*]furan-3-ilo

$C_{33}H_{41}N_3O_{10}S_2$



capeserodum

capeserod — 5-(8-amino-7-chloro-2,3-dihydro-1,4-benzodioxin-5-yl)-3-[1-(2-phenylethyl)piperidin-4-yl]-1,3,4-oxadiazol-2(3*H*)-one

capéserod — 5-(8-amino-7-chloro-2,3-dihydro-1,4-benzodioxin-5-yl)-3-[1-(2-phényléthyl)pipéridin-4-yl]-1,3,4-oxadiazol-2(3*H*)-one

capeserod — 5-(8-amino-7-cloro-2,3-dihidro-1,4-benzodioxin-5-il)-3-[1-(2-feniletil)piperidin-4-il]-1,3,4-oxadiazol-2(3*H*)-ona

$C_{23}H_{25}ClN_4O_4$



casopitantum

casopitant — (2*R*,4*S*)-4-(4-acetylpiperazin-1-yl)-*N*-{(1*R*)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl}-2-(4-fluoro-2-methylphenyl)-*N*-methylpiperidine-1-carboxamide

casopitant — (2*R*,4*S*)-4-(4-acétylpipérazin-1-yl)-*N*-[(1*R*)-1-[3,5-bis(trifluorométhyl)phényl]éthyl]-2-(4-fluoro-2-méthylphényl)-*N*-méthylpipéridine-1-carboxamide

casopitant — (2*R*,4*S*)-4-(4-acetilpiperazin-1-il)-*N*-[(1*R*)-1-[3,5-bis(trifluorometil)fenil]etil]-2-(4-fluoro-2-metilfenil)-*N*-metilpiperidin-1-carboxamida

$C_{30}H_{35}F_7N_4O_2$



celivaronum

celivarone — isopropyl 2-butyl-3-{4-[3-(dibutylamino)propyl]benzoyl}-1-benzofuran-5-carboxylate

célivarone — 2-butyl-3-[4-[3-(dibutylamino)propyl]benzoyl]benzofurane-5-carboxylate de 1-méthyléthyle

celivarona — 2-butil-3-{4-[3-(dibutilamino)propil]benzoil}-1-benzofurano-5-carboxilato de isopropilo

$C_{34}H_{47}NO_4$



cevoglitazarum

cevoglitazar — (2*R*)-1-{[4-({5-methyl-2-[4-(trifluoromethyl)phenyl]-1,3-oxazol-4-yl}=methoxy)phenyl]sulfonyl}-2,3-dihydro-1*H*-indole-2-carboxylic acid

cévoglitazar — acide (2*R*)-1-[[4-[[5-méthyl-2-[4-(trifluorométhyl)phényl]oxazol-4-yl]=méthoxy]phényl]sulfonyl]-2,3-dihydro-1*H*-indole-2-carboxylique

cevoglitazar — ácido (2*R*)-1-[[4-[[5-metil-2-[4-(trifluorometil)fenil]oxazol-4-il]metoxi]fenil]sulfonil]-2,3-dihidro-1*H*-indol-2-carboxílico

$C_{27}H_{21}F_3N_2O_6S$



darapladibum

darapladib — *N*-[2-(diethylamino)ethyl]-2-(2-{[(4-fluorophenyl)methyl]sulfanyl}-4-oxo-4,5,6,7-tetrahydro-1*H*-cyclopentapyrimidin-1-yl)-*N*-{[4'-(trifluoromethyl)biphenyl-4-yl]methyl}acetamide

darapladib — *N*-[2-(diéthylamino)éthyl]-2-[2-[(4-fluorobenzyl)sulfanyl]-4-oxo-4,5,6,7-tétrahydro-1*H*-cyclopentapyrimidin-1-yl]-*N*-[[4'-(trifluorométhyl)biphényl-4-yl]méthyl]acétamide

darapladib — *N*-[2-(dietilamino)etil]-2-[2-[(4-fluorobencil)sulfanil]-4-oxo-4,5,6,7-tetrahidro-1*H*-ciclopentapirimidin-1-il]-*N*-[[4'-(trifluorometil)=bifenil-4-il]metil]acetamida

$C_{36}H_{38}F_4N_4O_2S$



dasatinibum

dasatinib — *N*-(2-chloro-6-methylphenyl)-2-({6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl}amino)-1,3-thiazole-5-carboxamide

dasatinib — *N*-(2-chloro-6-méthylphényl)-2-[[6-[4-(2-hydroxyéthyl)pipérazin-1-yl]-2-méthylpyrimidin-4-yl]amino]thiazole-5-carboxamide

dasatinib — *N*-(2-cloro-6-metilfenil)-2-[[6-[4-(2-hidroxietil)piperazin-1-il]-2-metilpirimidin-4-il]amino]tiazol-5-carboxamida

$C_{22}H_{26}ClN_7O_2S$



denagliptinum

denagliptin — (2*S*,4*S*)-1-[(2*S*)-2-amino-3,3-bis(4-fluorophenyl)propanoyl]-4-fluoropyrrolidine-2-carbonitrile

dénagliptine — (2*S*,4*S*)-1-[(2*S*)-2-amino-3,3-bis(4-fluorophényl)propanoyl]-4-fluoropyrrolidine-2-carbonitrile

denagliptina — (2*S*,4*S*)-1-[(2*S*)-2-amino-3,3-bis(4-fluorofenil)propanoil]-4-fluoropirrolidina-2-carbonitrilo

$C_{20}H_{18}F_3N_3O$



denosumabum*

denosumab	immunoglobulin G2, anti-(human tumor necrosis factor ligand superfamily member 11 (human osteoclast differentiation factor)) (human monoclonal AMG162 heavy chain), disulfide with human monoclonal AMG162 light chain, dimer
dénosumab	immunoglobuline G2, anti-(11ème membre de la superfamille des ligands du facteur de nécrose tumorale (TNF) humain (facteur de différentiation de l'ostéoclaste)), dimère du disulfure entre la chaîne lourde et la chaîne légère de l'anticorps monoclonal humain AMG162
denosumab	inmunoglobulina G2, anti-(miembro nº 11 de la superfamilia de ligandos del factor de necrosis tumoral (TNF) humano (factor de diferenciación de osteoclastos)), dímero del disulfuro entre la cadena pesada y la cadena ligera del anticuerpo monoclonal humano AMG162

$C_{6404}H_{9908}N_{1724}O_{2004}S_{50}$

dexamethasoni cipecilas

dexamethasone cipecilate	9-fluoro-11β-hydroxy-16α-methyl-3,20-dioxopregna-1,4-diene-17,21-diyl 21-cyclohexanecarboxylate 17-cyclopropanecarboxylate
cipécilate de dexaméthasone	21-cyclohexanecarboxylate et 17-cyclopropanecarboxylate de 9-fluoro-11β-hydroxy-16α-méthyl-3,20-dioxoprégna-1,4-diène-17,21-diyle
cipecilato de dexametasona	17-ciclopropanocarboxilato 9-fluoro-11β-hidroxi-16α-metil-3,20-dioxopregna-1,4-dieno-17,21-diil 21-ciclohexanecarboxilato

$C_{33}H_{43}FO_7$



diaplasininum

diaplasinin	1-benzyl-3-pentyl-2-{6-[(1*H*-tetrazol-5-yl)methoxy]naphthalen-2-yl}-1*H*-indole
diaplasinine	1-benzyl-3-pentyl-2-[6-(1*H*-tétrazol-5-ylméthoxy)naphtalén-2-yl]-1*H*-indole
diaplasinina	1-bencil-3-pentil-2-{6-[(1*H*-tetrazol-5-il)metoxi]naftalen-2-il}-1*H*-indol

$C_{32}H_{31}N_5O$



dilopetinum

dilopetine — 2-[(2-methyl-1*H*-pyrazol-3-yl)(thiophen-2-yl)methoxy]-*N*,*N*-dimethylethanamine

dilopétine — *N*,*N*-diméthyl-2-[(*RS*)-(1-méthyl-1*H*-pyrazol-5-yl)(thiophén-2-yl)=méthoxy]éthanamine

dilopetina — 2-[(2-metil-1*H*-pirazol-3-il)(tiofen-2-il)metoxi]-*N*,*N*-dimetiletanamina

$C_{13}H_{19}N_3OS$



and enantiomer
et énantiomère
y enantiómero

disomotidum

disomotide — [186-L-methionine]melanocyte protein Pmel 17 (human melanoma-associated ME20 antigen)-(185-193)-peptide

disomotide — [186-L-méthionine]protéine Pmel 17 du mélanocyte humain (antigène ME20 associé au mélanome humain)-(185-193)-peptide

disomotida — [186-L-metionina]proteína Pmel 17 de melanocitos humanos (antígeno ME20 asociado al melanoma humano)-(185-193)-péptido

$C_{47}H_{74}N_{10}O_{14}S$

H—Ile—Met—Asp—Gln—Val—Pro—Phe—Ser—Val—OH

dutacatibum

dutacatib — *N*-({2-cyano-4-[(2,2-dimethylpropyl)amino]pyrimidin-5-yl}methyl)-4-(4-methylpiperazin-1-yl)benzamide

dutacatib — *N*-[[2-cyano-4-[(2,2-diméthylpropyl)amino]pyrimidin-5-yl]méthyl]-4-(4-méthylpipérazin-1-yl)benzamide

dutacatib — *N*-[[2-ciano-4-[(2,2-dimetilpropil)amino]pirimidin-5-il]metil]-4-(4-metilpiperazin-1-il)benzamida

$C_{23}H_{31}N_7O$



eltrombopagum

eltrombopag	3'-{(2*Z*)-2-[1-(3,4-dimethylphenyl)-3-methyl-5-oxo-1,5-dihydro-4*H*-pyrazol-4-ylidene]diazanyl}-2'-hydroxybiphenyl-3-carboxylic acid
eltrombopag	acide 3'-[(2*Z*)-2-[1-(3,4-diméthylphényl)-3-méthyl-5-oxo-1,5-dihydro-4*H*-pyrazol-4-ylidène]diazanyl]-2'-hydroxybiphényl-3-carboxylique
eltrombopag	ácido 3'-{(2*Z*)-2-[1-(3,4-dimetilfenil)-3-metil-5-oxo-1,5-dihidro-4*H*-pirazol-4-ilideno]diazanil}-2'-hidroxibifenil-3-carboxílico

$C_{25}H_{22}N_4O_4$



eprodisatum

eprodisate	propane-1,3-disulfonic acid
éprodisate	acide propane-1,3-disulfonique
eprodisato	ácid propano-1, 3-disulfónico

$C_3H_8O_6S_2$



fimasartanum

fimasartan	2-({2-butyl-4-methyl-6-oxo-1-{[2'-(1*H*-tetrazol-5-yl)biphenyl-4-yl]methyl}-1,6-dihydropyrimidin-5-yl})-*N*,*N*-dimethylthioacetamide
fimasartan	2-[2-butyl-4-méthyl-6-oxo-1-[[2'-(1*H*-tétrazol-5-yl)biphényl-4-yl]méthyl]-1,6-dihydropyrimidin-5-yl]-*N*,*N*-diméthylthioacétamide
fimasartán	2-({2-butil-4-metil-6-oxo-1-{[2'-(1*H*-tetrazol-5-il)bifenil-4-il]metil}-1,6-dihidropirimidin-5-il})-*N*,*N*-dimetiltioacetamida

$C_{27}H_{31}N_7OS$



fosaprepitantum

fosaprepitant	(3-{[(2*R*,3*S*)-2-{(1*R*)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy}-3-(4-fluorophenyl)morpholin-4-yl]methyl}-5-oxo-4,5-dihydro-1*H*-1,2,4-triazol-1-yl)phosphonic acid
fosaprépitant	acide [3-[[(2*R*,3*S*)-2-[(1*R*)-1-[3,5-bis(trifluorométhyl)phényl]éthoxy]-3-(4-fluorophényl)morpholin-4-yl]méthyl]-5-oxo-4,5-dihydro-1*H*-1,2,4-triazol-1-yl]phosphonique
fosaprepitant	ácido [3-[[(2*R*,3*S*)-2-[(1*R*)-1-[3,5-bis(trifluorometil)fenil]etoxi]-3-(4-fluorofenil)morfolin-4-il]metil]-5-oxo-4,5-dihidro-1*H*-1,2,4-triazol-1-il]fosfónico

$C_{23}H_{22}F_7N_4O_6P$



fospropofolum

fospropofol	dihydrogen (2,6-diisopropylphenoxy)methyl phosphate
fospropofol	dihydrogénophosphate de [2,6-bis(1-méthyléthyl)phénoxy]méthyle
fospropofol	dihidrógenofosfato de [2,6-bis(1-metiletil)fenoxi]metilo

$C_{13}H_{21}O_5P$



gabapentinum enacarbilum

gabapentin enacarbil	(1-{[({(1*RS*)-1-[(2-methylpropanoyl)oxy]ethoxy}carbonyl)amino]=methyl}cyclohexyl)acetic acid
gabapentine enacarbil	acide [1-[[[[(1*RS*)-1-[(2-méthylpropanoyl)oxy]éthoxy]carbonyl]=amino]méthyl]cyclohexyl]acétique

gabapentina enacarbilo

ácido (1-{[({(1*RS*)-1-[(2-metilpropanoil)oxi]etoxi}carbonil)amino]=metil}ciclohexil)acético

$C_{16}H_{27}NO_6$



and enantiomer
et énantiomère
y enantiómero

goxalapladibum

goxalapladib

2-{2-[2-(2,3-difluorophenyl)ethyl]-4-oxo-1,8-naphthyridin-1(4*H*)-yl}-*N*-[1-(2-methoxyethyl)piperidine-4-yl]-*N*-{[4'-(trifluoromethyl)biphenyl-4-yl]methyl}acetamide

goxalapladib

2-[2-[2-(2,3-difluorophényl)éthyl]-4-oxo-1,8-naphtyridin-1(4*H*)-yl]-*N*-[1-(2-méthoxyéthyl)pipéridin-4-yl]-*N*-[[4'-(trifluorométhyl)biphényl-4-yl]méthyl]acétamide

goxalapladib

2-[2-[2-(2,3-difluorofenil)etil]-4-oxo-1,8-naftiridin-1(4*H*)-il]-*N*-[1-(2-metoxietil)piperidin-4-il]-*N*-[[4'-(trifluorometil)bifenil-4-il]metil]acetamida

$C_{40}H_{39}F_5N_4O_3$



incyclinidum

incyclinide

(4a*S*,5a*R*,12a*S*)-3,10,12,12a-tetrahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide

incyclinide

(4a*S*,5a*R*,12a*S*)-3,10,12,12a-tétrahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotétracène-2-carboxamide

inciclinida

(4a*S*,5a*R*,12a*S*)-3,10,12,12a-tetrahidroxi-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahidrotetraceno-2-carboxamida

$C_{19}H_{17}NO_7$



indantadolum

indantadol — 2-[(2,3-dihydro-1*H*-inden-2-yl)amino]acetamide

indantadol — 2-[(2,3-dihydro-1*H*-indén-2-yl)amino]acétamide

indantadol — 2-[(2,3-dihidro-1*H*-inden-2-il)amino]acetamida

$C_{11}H_{14}N_2O$



ipilimumabum*

ipilimumab — immunoglobulin G1, anti-(human CTLA-4 (antigen)) (human γ1-chain), disulfide with human κ-chain, dimer

ipilimumab — immunoglobuline G1, anti-(antigène CTLA-4 humain), dimère du disulfure entre la chaîne γ1 et la chaîne κ de l'anticorps monoclonal humain

ipilimumab — inmunoglobulina G1, anti-(antígeno CTLA-4 humano), dímero del disulfuro entre la cadena γ1 y la cadena κ del anticuerpo monoclonal humano

$C_{6472}H_{9972}N_{1732}O_{2004}S_{40}$

iratumumabum*

iratumumab — immunoglobulin G1, anti-(Tumor necrosis factor ligand superfamily member 8 (CD30 ligand)) (human monoclonal MDX-060 heavy chain), disulfide with human monoclonal MDX-060 light chain, dimer

iratumumab — immunoglobuline G1, anti-(8ème membre de la superfamille des ligands du facteur de nécrose tumoral (TNF) humain), dimère du disulfure entre les chaînes lourde et légère de l'anticorps monoclonal humain NDX-060

iratumumab — inmunoglobulina G1, anti-(8° miembro de la superfamilia de ligandos del factor de necrosis tumoral (TNF) humano), dímero del disulfuro entre la cadena pesada y la cadena ligera del anticuerpo monoclonal humano NDX-060

$C_{6358}H_{9830}N_{1682}O_{1992}S_{38}$

larotaxelum

larotaxel — 1-hydroxy-9-oxo-5β,20-epoxy-7β,19-cyclotax-11-ene-2α,4,10β,13α-tetrayl 4,10-diacetate 2-benzoate 13-{(2*R*,3*S*)-3-[(*tert*-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoate}

larotaxel

(-)-7,12a-diacétate, 1-benzoate et 4-[(2*R*,3*S*)-3-[[(1,1-diméthyléthoxy)carbonyl]amino]-2-hydroxy-3-phenylpropanoate] (1*S*,2*S*,4*S*,5*E*,7*R*,8a*R*,9a*S*,10a*R*,12a*S*,12b*R*)-2-hydroxy-5,13,13-triméthyl-8-oxo-1,3,4,7,8,9,9a,10,10a,12b-décahydro-2,6-méthano-2*H*-cyclodeca[3,4]cyclopropa[4,5]benzo[1,2-*b*]oxète-1,4,7,12a(12*H*)-tétrayle

larotaxel

4,10-diacetato 2-benzoato 13-{(2*R*,3*S*)-3-[(*terc*-butoxicarbonil)=amino]-2-hidroxi-3-fenilpropanoato} de1-hidroxi-9-oxo-5β,20-epoxi-7β,19-ciclotax-11-eno-2α,4,10β,13α-tetrailo

$C_{45}H_{53}NO_{14}$



lisdexamfetaminum

lisdexamfetamine

(2*S*)-2,6-diamino-*N*-[(2*S*)-1-phenylpropan-2-yl]hexanamide

lisdexamfétamine

(2*S*)-2,6-diamino-*N*-[(1*S*)-1-méthyl-2-phényléthyl]hexanamide

lisdexanfetamina

(2*S*)-2,6-diamino-*N*-[(1*S*)-2-fenil-1-metiletil]hexanamida

$C_{15}H_{25}N_3O$



lodenafili carbonas

lodenafil carbonate

bis(2-{4-[4-ethoxy-3-(1-methyl-7-oxo-3-propyl-4,7-dihydro-1*H*-pyrazolo[4,3-*d*]pyrimidin-5-yl)phenylsulfonyl]piperazin-1-yl}ethyl) carbonate

lodénafil carbonate

carbonate de 2-[4-[[4-éthoxy-3-(1-méthyl-7-oxo-3-propyl-6,7-dihydro-1*H*-pyrazolo[4,3-*d*]pyrimidin-5-yl)phényl]sulfonyl]pipérazin-1-yl]éthyle

carbonato de lodenafilo

carbonato de bis(2-{4-[4-etoxi-3-(1-metil-7-oxo-3-propil-4,7-dihidro-1*H*-pirazolo[4,3-*d*]pirimidin-5-il)fenilsulfonil]piperazin-1-il}etil)

$C_{47}H_{62}N_{12}O_{11}S_2$



masilukastum

masilukast — 3-[(2-methoxy-4-{[(2-methylphenyl)sulfonyl]carbamoyl}phenyl)= methyl]-1-methyl-*N*-[(2*R*)-4,4,4-trifluoro-2-methylbutyl]-1*H*-indole-5-carboxamide

masilukast — 3-[2-méthoxy-4-[[(2-méthylphényl)sulfonyl]carbamoyl]benzyl]-1-méthyl-*N*-[(2*R*)-4,4,4-trifluoro-2-méthylbutyl]-1*H*-indole-5-carboxamide

masilukast — 1-metil-3-[(4-{[(2-metilfenil)sulfonil]carbamoil}fenil)metil-2-metoxi]-*N*-[(2*R*)-4,4,4-trifluoro-2-metilbutil]-1*H*-indol-5-carboxamida

$C_{31}H_{32}F_3N_3O_5S$



mavacoxibum

mavacoxib — 4-[5-(4-fluorophenyl)-3-(trifluoromethyl)-1*H*-pyrazol-1-yl]= benzenesulfonamide

mavacoxib — 4-[5-(4-fluorophényl)-3-(trifluorométhyl)-1*H*-pyrazol-1-yl]= benzènesulfonamide

mavacoxib — 4-[5-(4-fluorofenil)-3-(trifluorometil)-1*H*-pirazol-1-il]= bencenesulfonamida

$C_{16}H_{11}F_4N_3O_2S$



nilotinibum

nilotinib — 4-methyl-*N*-[3-(4-methyl-1*H*-imidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-{[4-(pyridin-3-yl)pyrimidin-2-yl]amino}benzamide

nilotinib — 4-méthyl-*N*-[3-(4-méthyl-1*H*-imidazol-1-yl)-5-(trifluorométhyl)phényl]-3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]benzamide

nilotinib — 4-metil-*N*-[3-(4-metil-1*H*-imidazol-1-il)-5-(trifluorometil)fenil]-3-{[4-(piridin-3-il)pirimidin-2-il]amino}benzamida

$C_{28}H_{22}F_3N_7O$



nimotuzumabum*

nimotuzumab — immunoglobulin G1, anti-(humanized mouse monoclonal hR3 ß1 chain anti-human epidermal growth factor receptor), disulfide with humanized mouse monoclonal hR3 κ-chain, dimer

nimotuzumab — immunoglobuline G1, anti-(récepteur du facteur de croissance des cellules de l'épiderme humain), dimère du disulfure entre la chaîne β1 et la chaîne κ de l'anticorps monoclonal de souris humanisé hR3

nimotuzumab — inmunoglobulina G1, anti-(receptor del factor de crecimiento de células de epidermis humana), dímero del disulfuro entre la cadena β1 y la cadena κ del anticuerpo monoclonal hR3 humanizado de ratón

$C_{6566}H_{10082}N_{1746}O_{2056}S_{40}$

obatoclaxum

obatoclax — 2-{2-[(3,5-dimethyl-1*H*-pyrrol-2-yl)methylidene]-3-methoxy-2*H*-pyrrol-5-yl}-1*H*-indole

obatoclax — 2-[2-[(3,5-diméthyl-1*H*-pyrrol-2-yl)méthylidène]-3-méthoxy-2*H*-pyrrol-5-yl]-1*H*-indole

obatoclax — 2-[2-[(3,5-dimetil-1*H*-pirrol-2-il)metilideno]-3-metoxi-2*H*-pirrol-5-il]-1*H*-indol

$C_{20}H_{19}N_3O$



ocrelizumabum*

ocrelizumab — immunoglobulin G1, anti-(human CD20 (antigen)) (human-mouse monoclonal 2H7 γ1-chain), disulfide with human-mouse monoclonal 2H7 κ-chain, dimer

ocrélizumab — immunoglobuline G1, anti-(antigène CD20 humain), dimère du disulfure entre la chaîne γ1 et la chaîne κ de l'anticorps monoclonal de souris humanisé 2H7

ocrelizumab — inmunoglobulina G1, anti-(antígeno) CD20 humano) dímero del disulfuro entre la cadena γ1 del anticuerpo monoclonal 2H7 hombre-ratón, y la cadena-κ del anticuerpo monoclonal 2H7 hombre-ratón

$C_{6494}H_{9978}N_{1718}O_{2014}S_{46}$

oglemilastum

oglemilast — *N*-(3,5-dichloropyridin-4-yl)-4-(difluoromethoxy)-8-[(methylsulfonyl)=amino]dibenzo[*b*,*d*]furan-1-carboxamide

oglémilast — *N*-(3,5-dichloropyridin-4-yl)-4-(difluoromethoxy)-8-[(methylsulfonyl)=amino]dibenzo[*b*,*d*]furan-1-carboxamide

oglemilast — *N*-(3,5-dicloropiridin-4-il)-4-(difluorometoxi)-8-[(metilsulfonil)=amino]dibenzo[*b*,*d*]furano-1-carboxamida

$C_{20}H_{13}Cl_2F_2N_3O_5S$



olaparibum

olaparib — 4-[(3-{[4-(cyclopropylcarbonyl)piperazin-1-yl]carbonyl}-4-fluorophenyl)methyl]phthalazin-1(2*H*)-one

olaparib — 1-(cyclopropylcarbonyl)-4-[2-fluoro-5-[(4-oxo-3,4-dihydrophtalazin-1-yl)méthyl]benzoyl]pipérazine

olaparib — 1-(ciclopropilcarbonil)-4-[2-fluoro-5-[(4-oxo-3,4-dihidroftalazin-1-il)metil]benzoil]piperazina

$C_{24}H_{23}FN_4O_3$



orvepitantum

orvepitant (2*R*,4*S*)-*N*-{(1*R*)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl}-2-(4-fluoro-2-methylphenyl)-*N*-methyl-4-[(8a*S*)-6-oxohexahydro-1*H*-pyrrolo=[1,2-*a*]pyrazin-2-yl]piperidine-1-carboxamide

orvépitant (2*R*,4*S*)-*N*-[(1*R*)-1-[3,5-bis(trifluorométhyl)phényl]éthyl]-2-(4-fluoro-2-méthylphényl)-*N*-méthyl-4-[(8a*S*)-6-oxohexahydropyrrolo=[1,2-*a*]pyrazin-2(1*H*)-yl]pipéridine-1-carboxamide

orvepitant (2*R*,4*S*)-*N*-[(1*R*)-1-[3,5-bis(trifluorometil)fenil]etill]-2-(4-fluoro-2-metilfenil)-*N*-metil-4-[(8a*S*)-6-oxohexahidropirrolo[1,2-*a*]pirazin-2(1*H*)-il]piperidina-1-carboxamida

$C_{31}H_{35}F_7N_4O_2$



ovemotidum

ovemotide [264-L-valine]melanocyte protein Pmel 17 (human melanoma-associated ME20 antigen)-(256-264)-peptide

ovémotide [264-L-valine]protéine Pmel 17 du mélanocyte humain (antigène ME20 associé au mélanome humain)-(256-264)-peptide

ovemotida [264-L-valina]proteína Pmel 17 de melanocitos humanos (antígeno ME20 asociado al melanoma humano)-(256-264)-péptido

$C_{46}H_{71}N_9O_{14}$

H–Tyr–Leu–Glu–Pro–Gly–Pro–Val–Thr–Val–OH

ozarelixum

ozarelix *N*-acetyl-3-(naphthalen-2-yl)-D-alanyl-4-chloro-D-phenylalanyl-3-(pyridin-3-yl)-D-alanyl-L-seryl-*N*-methyl-L-tyrosyl-N^6-carbamoyl-D-lysyl-L-2-aminohexanoyl-L-arginyl-L-prolyl-D-alaninamide

ozarélix *N*-acétyl-3-(naphthalén-2-yl)-D-alanyl-4-chloro-D-phénylalanyl-3-(pyridin-3-yl)-D-alanyl-L-séryl-*N*-méthyl-L-tyrosyl-N^6-carbamoyl-D-lysyl-L-2-aminohexanoyl-L-arginyl-L-prolyl-D-alaninamide

ozarelix

N-acetil-3-(naftalen-2-il)-D-alanil-4-cloro-D-fenilalanil-3-(piridin-3-il)-D-alanil-L-seril-*N*-metil-L-tirosil-N^6-carbamoil-D-lisil-L-2-aminohexanoil-L-arginil-L-prolil-D-alaninamida

$C_{72}H_{96}ClN_{17}O_{14}$



paquinimodum

paquinimod

N,5-diethyl-4-hydroxy-1-methyl-2-oxo-*N*-phenyl-1,2-dihydroquinoline-3-carboxamide

paquinimod

N,5-diéthyl-4-hydroxy-1-méthyl-2-oxo-*N*-phényl-1,2-dihydroquinoléine-3-carboxamide

paquinimod

N,5-dietil-4-hidroxi-1-metil-2-oxo-*N*-fenil-1,2-dihidroquinolina-3-carboxamida

$C_{21}H_{22}N_2O_3$



parogrelilum

parogrelil

4-bromo-6-[3-(4-chlorophenyl)propoxy]-5-[(pyridin-3-ylmethyl)=amino]pyridazin-3(2*H*)-one

parogrélil

4-bromo-6-[3-(4-chlorophényl)propoxy]-5-[(pyridin-3-ylméthyl)=amino]pyridazin-3(2*H*)-one

parogrelilo

4-bromo-6-[3-(4-clorofenil)propoxi]-5-[(piridin-3-ilmetil)=amino]piridazin-3(2*H*)-ona

$C_{19}H_{18}BrClN_4O_2$



pazopanibum

pazopanib — 5-({4-[(2,3-dimethyl-2*H*-indazol-6-yl)methylamino]pyrimidin-2-yl}amino)-2-methylbenzenesulfonamide

pazopanib — 5-[[4-[(2,3-diméthyl-2*H*-indazol-6-yl)méthylamino]pyrimidin-2-yl]amino]-2-méthylbenzènesulfonamide

pazopanib — 5-({4-[(2,3-dimetil-2*H*-indazol-6-il)metilamino]pirimidin-2-il}amino)-2-metilbencenosulfonamida

$C_{21}H_{23}N_7O_2S$



relacatibum

relacatib — *N*-[(1*S*)-3-methyl-1-{[(4*S*,7*R*)-7-methyl-3-oxo-1-(pyridin-2-ylsulfonyl)=hexahydro-1*H*-azepin-4-yl]carbamoyl}butyl]-1-benzofuran-2-carboxamide

rélacatib — *N*-[(1*S*)-3-méthyl-1-[[(4*S*,7*R*)-7-méthyl-3-oxo-1-(pyridin-2-ylsulfonyl)=hexahydro-1*H*-azépin-4-yl]carbamoyl]butyl]benzofurane-2-carboxamide

relacatib — *N*-[(1*S*)-3-metil-1-{[(4*S*,7*R*)-7-metil-3-oxo-1-(piridin-2-ilsulfonil)=hexahidro-1*H*-azepin-4-il]carbamoil}butil]-1-benzofuran-2-carboxamida

$C_{27}H_{32}N_4O_6S$



rilapladibum

rilapladib — 2-(2-{[(2,3-difluorophenyl)methyl]sulfanyl}-4-oxoquinolin-1(4*H*)-yl)-*N*-[1-(2-methoxyethyl)piperidin-4-yl]-*N*-{[4'-(trifluoromethyl)biphenyl-4-yl]methyl}acetamide

rilapladib — 2-[2-[(2,3-difluorobenzyl)sulfanyl]-4-oxoquinoléin-1(4*H*)-yl]-*N*-[1-(2-méthoxyéthyl)pipéridin-4-yl]-*N*-[[4'-(trifluorométhyl)biphényl-4-yl]méthyl]acétamide

rilapladib — 2-[2-[(2,3-difluorobencil)sulfanil]-4-oxoquinolin-1(4*H*)-il]-*N*-[1-(2-metoxietil)piperidin-4-il]-*N*-[[4'-(trifluorometil)bifenil-4-il]metil]acetamida

$C_{40}H_{38}F_5N_3O_3S$



rolipoltidum

rolipoltide — protein derived from two major allergens of *Cryptomeria japonica* pollen: Sugi basic protein (Cry j 1) and the polygalacturonase (Cry j 2):
(Cry j 1-(213-225)-peptidyl)-L-arginyl-L-arginyl(Cry j 1-(108-120)-peptidyl)-L-arginyl-L-arginyl(Cry j 2-(191-209)-peptidyl)-L-arginyl-L-arginyl(Cry j 2-(88-107)-peptidyl)-L-arginyl-L-arginyl(Cry j 1-(80-95)-peptidyl)-L-arginyl(Cry j 2-(75-89)-peptide)

rolipoltide — protéine dérivée de deux principaux allergènes de pollen du cèdre du Japon, *Cryptomeria japonica*, la protéine basique Sugi (Cry j 1) et la polygalacturonase (Cry j 2) :
(Cry j 1-(213-225)-peptidyl)-L-arginyl-L-arginyl(Cry j 1-(108-120)-peptidyl)-L-arginyl-L-arginyl(Cry j 2-(191-209)-peptidyl)-L-arginyl-L-arginyl(Cry j 2-(88-107)-peptidyl)-L-arginyl-L-arginyl(Cry j 1-(80-95)-peptidyl)-L-arginyl(Cry j 2-(75-89)-peptide)

rolipoltida — proteína derivada de dos de los alérgenos principales del polen del cedro de Japón,*Cryptomeria japonica* : la proteína básica Sugi (Cry j 1) y la poligalacturonasa (Cry j 2) :
(Cry j 1-(213-225)-peptidil)-L-arginil-L-arginil(Cry j 1-(108-120)-peptidil)-L-arginil-L-arginil(Cry j 2-(191-209)-peptidil)-L-arginil-L-arginil(Cry j 2-(88-107)-peptidil)-L-arginil-L-arginil(Cry j 1-(80-95)-peptidil)-L-arginil(Cry j 2-(75-89)-péptido)

$C_{561}H_{887}N_{169}O_{136}S_4$

```
MKVTVAFNQF GPNRRVFIKR VSNVIIHGRR IDIFASKNFH 40
LQKNTIGTGR RWKNNRIWLQ FAKLTGFTLM GRRLKMPMYI 80
AGYKTFDGRR VDGIIAAYQN PASWK                105
```

romidepsinum

romidepsin — (1*S*,4*S*,10*S*,16*E*,21*R*)-7-[(2*Z*)ethylidene]-4,21-diisopropyl-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone

romidepsine — (1*S*,4*S*,7*Z*,10*S*,16*E*,21*R*)-7-éthylidène-4,21-bis(1-méthyléthyl)-2-oxa-12,13-dithia-5,8,20,23-tétraazabicyclo[8.7.6]tricos-16-ène-3,6,9,19,22-pentone

romidepsina — (1*S*,4*S*,10*S*,16*E*,21*R*)-7-[(2*Z*)etilideno]-4,21-diisopropil-2-oxa-12,13-ditia-5,8,20,23-tetraazabiciclo[8.7.6]tricos-16-eno-3,6,9,19,22-pentona

$C_{24}H_{36}N_4O_6S_2$



rotigaptidum

rotigaptide	*N*-acetyl-D-tyrosyl-D-prolyl-(4*S*)-4-hydroxy-D-prolylglycyl-D-alanylglycinamide
rotigaptide	acétyl-D-tyrosyl-D-prolyl-(4*S*)-4-hydroxy-D-prolylglycyl-D-alanylglycinamide
rotigaptida	acetil-D-tirosil-D-prolil-(4*S*)-4-hidroxi-D-prolilglicil-D-alanilglicinamida

$C_{28}H_{39}N_7O_9$



sapacitabinum

sapacitabine	*N*-[1-(2-cyano-2-deoxy-β-D-arabinofuranosyl]-2-oxo-1,2-dihydropyrimidin-4-yl}hexadecanamide
sapacitabine	*N*-[1-(2-cyano-2-désoxy-β-D-arabinofuranosyl)-2-oxo-1,2-dihydropyrimidin-4-yl]hexadécanamide
sapacitabina	*N*-[1-(2-ciano-2-desoxi-β-D-arabinofuranosil]-2-oxo-1,2-dihidropirimidin-4-il}hexadecanamida

$C_{26}H_{42}N_4O_5$



simotaxelum

simotaxel — 1,7β-dihydroxy-9-oxo-5β,20-epoxytax-11-ene-2α,4,10β,13α-tetrayl 4-acetate 2-benzoate 10-cyclopentanecarboxylate 13-{(2*R*,3*R*)-2-hydroxy-3-(isopropoxycarbonyl)amino]-3-(thiophen-2-yl)propanoate}

simotaxel — 12b-acétate 12-benzoate 6-cyclopentanecarboxylate et 9-[(2*R*,3*R*)-2-hydroxy-3-[[(1-méthyléthoxy)carbonyl]amino]-3-(thiophén-2-yl)propanoate] de (2a*R*,4*S*,4a*S*,6*R*,9*S*,11*S*,12*S*,12a*R*,12b*S*)-4,11-dihydroxy-4a,8,13,13-tétraméthyl-5-oxo-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodécahydro-7,11-méthano-1*H*-cyclodéca[3,4]benz[1,2-*b*]oxète-6,9,12,12b-tétrayle

simotaxel — 12b-acetato 12-benzoato 6-ciclopentanocarboxilato y 9-[(2*R*,3*R*)-2-hidroxi-3-[[(1-metiletoxi)carbonil]amino]-3-(tiofen-2-il)propanoato] de (2a*R*,4*S*,4a*S*,6*R*,9*S*,11*S*,12*S*,12a*R*,12b*S*)-4,11-dihidroxi-4a,8,13,13-tetrametil-5-oxo-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahidro-7,11-metano-1*H*-ciclodeca[3,4]benz[1,2-*b*]oxeto-6,9,12,12b-tetrailo

$C_{46}H_{57}NO_{15}S$



sitagliptinum

sitagliptin — (3*R*)-3-amino-1-[3-(trifluoromethyl)-5,6,7,8-tetrahydro-5*H*-[1,2,4]triazolo[4,3-*a*]pyrazin-7-yl]-4-(2,4,5-trifluorophenyl)butan-1-one

sitagliptine — 7-[(3*R*)-3-amino-4-(2,4,5-trifluorophényl)butanoyl]-3-(trifluorométhyl)-5,6,7,8-tétrahydro-1,2,4-triazolo[4,3-*a*]pyrazine

sitagliptina — 7-[(3*R*)-3-amino-4-(2,4,5-trifluorofenil)butanoil]-3-(trifluorometil)-5,6,7,8-tetrahidro-1,2,4-triazolo[4,3-*a*]pirazina

$C_{16}H_{15}F_6N_5O$



sontuzumabum

sontuzumab	immunoglobulin G1, anti-(human episialin) (mouse monoclonal HMFG-1 γ1-chain), disulfide with mouse monoclonal HMFG-1, dimer
sontuzumab	immunoglobuline G1, anti-(épisialine, spécifique de l'épitope APDTR) ; dimère du disulfure entre la chaîne γ1 et la chaîne légère de l'anticorps monoclonal de souris HMFG-1
sontuzumab	inmunoglobulina G1, anti-(human episialina) dímero del disulfuro entre la cadena HMFG-1 γ1 monoclonal de ratón y la cadena ligera HMFG-1 monoclonal de ratón

sotirimodum

sotirimod	2-methyl-1-(2-methylpropyl)-1*H*-imidazo[4,5-*c*][1,5]naphthyridin-4-amine
sotirimod	2-méthyl-1-(2-méthylpropyl)-1*H*-imidazo[4,5-*c*][1,5]naphtyridin-4-amine
sotirimod	2-metil-1-(2-metilpropil)-1*H*-imidazo[4,5-*c*][1,5]naftiridin-4-amina
	$C_{14}H_{17}N_5$



stamulumabum*

stamulumab	immunoglobulin G1, anti-(human growth differentiation factor 8) (human MYO-029 heavy chain), disulfide with human MYO-029 λ-chain, dimer
stamulumab	immunoglobuline G1, anti-(facteur 8 de croissance/différenciation (GDF-8 ou myostatine) humain) ; dimère du disulfure entre la chaîne lourde et la chaîne λ de l'anticorps monoclonal humain MYO-029
estamulumab	inmunoglobulina G1, anti-(factor 8 de diferenciación del crecimiento humano) dímero del disulfuro entre la cadena pesada de MYO-029 humano y la cadena λ de MYO-029 humano
	$C_{6330}H_{9748}N_{1672}O_{1998}S_{48}$

tadocizumabum*

tadocizumab	immunoglobulin G1, anti-(human integrin αIIbβ3) Fab fragment (human-mouse monoclonal C4G1 γ1-chain), disulfide with human-mouse monoclonal C4G1 κ-chain
tadocizumab	immunoglobuline G1, anti-(intégrine αIIbβ3 humaine), disulfure entre la chaîne γ1 et la chaîne κ du fragment Fab de l'anticorps monoclonal de souris C4G1 humanisé

tadocizumab

inmunoglobulina G1, anti-(integrina humana αIIbβ3) disulfuro entre el fragmento Fab de la C4G1 cadena γ1 del anticuerpo monoclonal hombre-ratón, y la cadena κ del anticuerpo monoclonal hombre-ratón C4G1

$C_{2107}H_{3252}N_{562}O_{673}S_{12}$

```
                                 QVQLVQSGAE VKKPGSSVKV
DIQMTQTPST LSASVGDRVT    SCKASGYAFT NYLIEWVRQA
ISCRASQDIN NYLNWYQQKP    PGQGLEWIGV IYPGSGGTNY
GKAPKLLIYY TSTLHSGVPS    NEKFKGRVTL TVDESTNTAY
RFSGSGSGTD YTLTISSLQP    MELSSLRSED TAVYFCARRD
DDFATYFCQQ GNTLPWTFGQ    GNYGWFAYWG QGTLVTVSSA
GTKVEVKRTV AAPSVFIFPP    STKGPSVFPL APSSKSTSGG
SDEQLKSGTA SVVCLLNNFY    TAALGCLVKD YFPEPVTVSW
PREAKVQWKV DNALQSGNSQ    NSGALTSGVH TFPAVLQSSG
ESVTEQDSKD STYSLSSTLT    LYSLSSVVTV PSSSLGTQTY
LSKADYEKHK VYACEVTHQG    ICNVNHKPSN TKVDKKVEPK
LSSPVTKSFN RGEC          SCDKTH
```

talotrexinum

talotrexin

2-{[(4*S*)-4-carboxy-4-(4-{[(2,4-diaminopteridin-6-yl)methyl]amino}benzamido)butyl]carbamoyl}benzoic acid

talotrexine

acide 2-[[(4*S*)-4-carboxy-4-[[4-[[(2,4-diaminoptéridin-6-yl)méthyl]amino]benzoyl]amino]butyl]carbamoyl]benzoïque

talotrexina

ácido 2-[[(4*S*)-4-carboxi-4-[[4-[[(2,4-diamino-6-pteridinil)metil]amino]benzoil]amino]butil]carbamoil]benzoico

$C_{27}H_{27}N_9O_6$



telaprevirum

telaprevir

(1*S*,3a*R*,6a*S*)-2-[(2*S*)-2-{(2*S*)-cyclohexyl[(pyrazin-2-ylcarbonyl)amino]acetamido}-3,3-dimethylbutanoyl]-*N*-{(3*S*)-1-cyclopropylamino)-1,2-dioxohexan-3-yl}octahydrocyclopenta[*c*]pyrrole-1-carboxamide

télaprévir

(1*S*,3a*R*,6a*S*)-2-[(2*S*)-2-[[(2*S*)-cyclohexyl[(pyrazinylcarbonyl)amino]étyl]amino]-3,3-diméthylbutanoyl]-*N*-[(1*S*)-1-[(cyclopropylamino)oacétyl]butyl]octahydrocyclopenta= [*c*]pyrrole-1-carboxamide

telaprevir

1*S*,3a*R*,6a*S*)-2-[(2*S*)-2-[[(2*S*)-ciclohexil[(pirazinilcarbonil)amino]acetil]amino]-3,3-dimetilbutanoil]-*N*-[(1*S*)-1-[(ciclopropilamino)oxoacetil]butil]octahidrociclopenta[*c*]pirrol-1carboxamida

$C_{36}H_{53}N_7O_6$



tiplasininum

tiplasinin	2-{1-benzyl-5-[4-(trifluoromethoxy)phenyl]-1*H*-indole-3-yl}-2-oxoacetic acid
tiplasinine	acide [1-benzyl-5-[4-(triflorométhoxy)phényl]-1*H*-indol-3-yl]oxoacétique
tiplasinina	ácido 2-{1-bencil-5-[4-(trifluorometoxi)fenil]-1*H*-indol-3-il}-2-oxoacético

$C_{24}H_{16}F_3NO_4$



tramiprosatum

tramiprosate	3-aminopropane-1-sulfonic acid
tramiprosate	acide 3-aminopropane-1-sulfonique
tramiprosato	ácido 3-aminopropano-1-sulfónico

$C_3H_9NO_3S$



transferrinum aldifitoxum

transferrin aldifitox	a conjugate of the precursor of human serotransferrin (siderophillin) with a primary amine group used to form an amidine with (4-iminobutane-1,4-diyl)sulfanediyl[(3RS)-2,5-dioxopyrrolidine-1,3-diyl]-1,3-phenylenecarbonyl and forming an *N*-benzoyl derivative of a primary amine group of diphtheria [550-L-phenylalanine]toxin from *Corynebacterium diphtheriae*-(26-560)-peptide
transferrine aldifitox	précurseur de la sérotransferrine humaine (sidérophilline) dont une fonction amine primaire est liée par une fonction carboximidamide (amidine) au pont (4-iminobutane-1,4-diyl)sulfanediyl[(3RS)-2,5-dioxopyrrolidine -1,3-diyl]-1,3-phénylènecarbonyl lui-même lié par une fonction benzamide à une amine primaire du [550-L-phénylalanine]toxine diphtérique de *Corynebacterium diphteriae*-(26-560)-peptide

transferrina aldifitox

precursor de la serotransferrina humana (siderofilina) en el cual una función amina primaria está ligada por una función carboximidamida (amidina) al puente (4-iminobutano-1,4-diil)sulfanodiil[(3RS)-2,5-dioxopirrolidina-1,3-diil]-1,3-fenilenocarbonil ligado a su vez por una función benzamida una amina primaria de la [550-L-fenilalanina]toxina diftérica del *Corynebacterium diphteriae*-(26-560)-péptido

$C_{5992}H_{9317}N_{1641}O_{1834}S_{63}$



and epimer at C*
et l'épimère en C*
y el epímero al C*

Tf-NH_2=

MRLAVGALLV CAVLGLCLAV PDKTVRWCAV SEHEATKCQS
FRDHMKSVIP SDGPSVACVK KASYLDCIRA IAANEADAVT
LDAGLVYDAY LAPNNLKPVV AEFYGSKEDP QTFYYAVAVV
KKDSGFQMNQ LRGKKSCHTG LGRSAGWNIP IGLLYCDLPE
PRKPLEKAVA NFFSGSCAPC ADGTDFPQLC QLCPGCGCST
LNQYFGYSGA FKCLKDGAGD VAFVKHSTIF ENLANKADRD
QYELLCLDNT RKPVDEYKDC HLAQVPSHTV VARSMGGKED
LIWELLNQAQ EHFGKDKSKE FQLFSSPHGK DLLFKDSAHG
FLKVPPRMDA KMYLGYEYVT AIRNLREGTC PEAPTDECKP
VKWCALSHHE RLKCDEWSVN SVGKIECVSA ETTEDCIAKI
MNGEADAMSL DGGFVYIAGK CGLVPVLAEN YNKSDNCEDT
PEAGYFAVAV VKKSASDLTW DNLKGKKSCH TAVGRTAGWN
IPMGLLYNKI NHCRFDEFFS EGCAPGSKKD SSLCKLCMGS
GLNLCEPNNK EGYYGYTGAF RCLVEKGDVA FVKHQTVPQN
TGGKNPDPWA KNLNEKDYEL LCLDGTRKPV EEYANCHLAR
APNHAVVTRK DKEACVHKIL RQQQHLFGSN VTDCSGNFCL
FRSETKDLLF RDDTVCLAKL HDRNTYEKYL GEEYVKAVGN
LRKCSTSSLL EACTFRRP

* glycosylation sites
* sites de glycosylation
* posiciónes de glicosilación

H_2N-CRM107=

GADDVVDSSK SFVMENFSSY HGTKPGYVDS IQKGIQKPKS
GTQGNYDDDW KGFYSTDNKY DAAGYSVDNE NPLSGKAGGV
VKVTYPGLTK VLALKVDNAE TIKKELGLSL TEPLMEQVGT
EEFIKRFGDG ASRVVLSLPF AEGSSSVEYI NNWEQAKALS
VELEINFETR GKRGQDAMYE YMAQACAGNR VRRSVGSSLS
CINLDWDVIR DKTKTKIESL KEHGPIKNKM SESPNKTVSE
EKAKQYLEEF HQTALEHPEL SELKTVTGTN PVFAGANYAA
WAVNVAQVID SETADNLEKT TAALSILPGI GSVMGIADGA
VHHNTEEIVA QSIALSSLMV AQAIPLVGEL VDIGFAAYNF
VESIINLFQV VHNSYNRPAY SPGHKTQPFL HDGYAVSWNT
VEDSIIRTGF QGESGHDIKI TAENTPLPIA GVLLPTIPGK
LDVNKSKTHI SVNGRKIRMR CRAIDGDVTF CRPKSPVYVG
NGVHANLHVA FHRSSSEKIH SNEISSDSIG VLGYQKTVDH
TKVNFKLSLF FEIKS

tucotuzumabum celmoleukinum*

tucotuzumab celmoleukin	immunoglobulin G1, anti-(tumor associated calcium signal transducer 1 (KS 1/4 antigen)) (human-mouse monoclonal huKS-IL2 heavy chain) fusion protein with interleukin 2 (human), disulfide with human-mouse monoclonal huKS-IL2 light chain, dimer
tucotuzumab celmoleukine	immunoglobuline G1, anti-(transducteur 1 du signal calcique associé aux cellules tumorales humaines), dimère du disulfure entre le peptide de fusion de la chaîne lourde, de l'anticorps monoclonal de souris huKS-IL2 humanisé, avec l'interleukine 2 humaine, et la chaîne légère de l'anticorps monoclonal de souris huKS-IL2 humanisé
tucotuzumab celmoleukina	inmunoglobulina G1, anti-(antígeno 17-1A humano) dímero del disulfuro entre la proteína de fusión de la cadena pesada del anticuerpo monoclonal huKS-IL2 hombre-ratón y la interleukina 2 (humana), y la cadena ligera del anticuerpo monoclonal huKS-IL2 hombre-ratón

$C_{7812}H_{12114}N_{2042}O_{2406}S_{60}$

velaferminum*

velafermin	fibroblast growth factor 20 (human recombinant CG53135)
vélafermine	facteur-20 de croissance du fibroblaste humain recombinant (CG53135)
velafermina	factor 20 de crecimiento de fibroblastos (recombinante humano CG53135)

$C_{1047}H_{1632}N_{306}O_{302}S_5$

MAPLAEVGGF LGGLEGLGQQ VGSHFLLPPA GERPPLLGER
RSAAERSARG GPGAAQLAHL HGILRRRQLY CRTGFHLQIL
PDGSVQGTRQ DHSLFGILEF ISVAVGLVSI RGVDSGLYLG
MNDKGELYGS EKLTSECIFR EQFEENWYNT YSSNIYKHGD
TGRRYFVALN KDGTPRDGAR SKRHQKFTHF LPRPVDPERV
PELYKDLLMY T

verpasepum caltespenum*

verpasep caltespen	60 kDa chaperonin 2 (HSP 65 from *Mycobacterium bovis* strain BCG) fusion protein with L-histidylprotein E7 from human papillomavirus type 16
verpasep caltespen	60 kDa chaperonine 2 (HSP 65 de *Mycobacterium bovis* souche BCG) protéine de fusion avec la L-histidylprotéine E7 de papillomavirus de type 16 humain
verpasep caltespeno	60 kDa chaperonina 2 (HSP 65 de *Mycobacterium bovis* cepa BCG) proteína de fusión con la L-histidilproteína E7 del papilomavirus humano 16

$C_{2959}H_{4860}N_{810}O_{965}S_{16}$

AKTIAYDEEA	RRGLERGLNA	LADAVKVTLG	PKGRNVVLEK
KWGAPTITND	GVSIAKEIEL	EDPYEKIGAE	LVKEVAKKTD
DVAGDGTTTA	TVLAQALVRE	GLRNVAAGAN	PLGLKRGIEK
AVEKVTETLL	KGAKEVETKE	QIAATAAISA	GDQSIGDLIA
EAMDKVGNEG	VITVEESNTF	GLQLELTEGM	RFDKGYISGY
FVTDPERQEA	VLEDPYILLV	SSKVSTVKDL	LPLLEKVIGA
GKPLLIIAED	VEGEALSTLV	VNKIRGTFKS	VAVKAPGFGD
RRKAMLQDMA	ILTGGQVISE	EVGLTLENAD	LSLLGKARKV
VVTKDETTIV	EGAGDTDAIA	GRVAQIRQEI	ENSDSDYDRE
KLQERLAKLA	GGVAVIKAGA	ATEVELKERK	HRIEDAVRNA
KAAVEEGIVA	GGGVTLLQAA	PTLDELKLEG	DEATGANIVK
VALEAPLKQI	AFNSGLEPGV	VAEKVRNLPA	GHGLNAQTGV
YEDLLAAGVA	DPVKVTRSAL	QNAASIAGLF	LTTEAVVADK
PEKEKASVPG	GGDMGGMDFH	MHGDTPTLHE	YMLDLQPETT
DLYCYEQLND	SSEEEDEIDG	PAGQAEPDRA	HYNIVTFCCK
CDSTLRLCVQ	STHVDIRTLE	DLLMGTLGIV	CPICSQKP

vicrivirocum

vicriviroc (4,6-dimethylpyrimidin-5-yl){4-[(3S)-4-{(1R)-2-methoxy-1-[4-(trifluoromethyl)phenyl]ethyl}-3-methylpiperazin-1-yl]-4-methylpiperidin-1-yl}methanone

vicriviroc 1-[(4,6-diméthylpyrimidin-5-yl)carbonyl]-4-[(3*S*)-4-[(1*R*)-2-méthoxy-1-[4-(trifluorométhyl)phényl]éthyl]-3-méthylpipérazin-1-yl]-4-méthylpipéridine

vicriviroc (4,6-dimetilpirimidin-5-il){4-[(3*S*)-4-{(1*R*)-2-metoxi-1-[4-(trifluorometil)fenil]etil}-3-metilpiperazin-1-il]-4-metilpiperidin-1-il}metanona

$C_{28}H_{38}F_3N_5O_2$



vorinostatum

vorinostat *N*-hydroxy-*N*′-phenyloctanediamide

vorinostat *N*-hydroxy-*N*′-phényloctanediamide

vorinostat *N*-hidroxi-*N*′-feniloctanodiamido

$C_{14}H_{20}N_2O_3$



zibotentanum

zibotentan	*N*-(3-methoxy-5-methylpyrazin-2-yl)-2-[4-(1,3,4-oxadiazol-2-yl)phenyl]pyridine-3-sulfonamide
zibotentan	*N*-(3-méthoxy-5-méthylpyrazin-2-yl)-2-[4-(1,3,4-oxadiazol-2-yl)phényl]pyridine-3-sulfonamide
zibotentán	*N*-(3-metoxi-5-metilpirazin-2-il)-2-[4-(1,3,4-oxadiazol-2-il)fenil]piridine-3-sulfonamida

$C_{19}H_{16}N_6O_4S$



zotarolimusum

zotarolimus	(3*S*,6*R*,7*E*,9*R*,10*R*,12*R*,14*S*,15*E*,17*E*,19*E*,21*S*,23*S*,26*R*,27*R*,34a*S*)-9,27-dihydroxy-10,21-dimethoxy-3-{(2*R*)-1-[(1*S*,3*R*,4*S*)-3-methoxy-4-(1*H*-tetrazol-1-yl)cyclohexyl]propan-2-yl}-6,8,12,14,20,26-hexamethyl-3,4,9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-octadecahydro-5*H*-23,27-epoxypyrido[2,1-*c*][1,4]oxaazahentriacontine-1,5,11,28,29(6*H*,31*H*)-pentone
zotarolimus	(3*S*,6*R*,7*E*,9*R*,10*R*,12*R*,14*S*,15*E*,17*E*,19*E*,21*S*,23*S*,26*R*,27*R*,34a*S*)-9,27-dihydroxy-10,21-diméthoxy-3-[(1*R*)-2-[(1*S*,3*R*,4*S*)-3-méthoxy-4-(1*H*-tétrazol-1-yl)cyclohexyl]-1-méthyléthyl]-6,8,12,14,20,26-hexaméthyl-3,4,9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-octadécahydro-23,27-époxy-5*H*-pyrido[2,1-*c*][1,4]oxazahentriacontine-1,5,11,28,29(6*H*,31*H*)-pentone
zotarolimus	(3*S*,6*R*,7*E*,9*R*,10*R*,12*R*,14*S*,15*E*,17*E*,19*E*,21*S*,23*S*,26*R*,27*R*,34a*S*)-9,27-dihidroxi-10,21-dimetoxi-3-{(2*R*)-1-[(1*S*,3*R*,4*S*)-3-metoxi-4-(1*H*-tetrazol-1-il)ciclohexil]propan-2-il}-6,8,12,14,20,26-hexametil-3,4,9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-octadecahidro-5*H*-23,27-epoxipirido[2,1-*c*][1,4]oxaazahentriacontina-1,5,11,28,29(6*H*,31*H*)-pentona

$C_{52}H_{79}N_5O_{12}$



* Electronic structure available on Mednet: http://mednet.who.int/
* Structure électronique disponible sur Mednet: http://mednet.who.int/
* Estructura electrónica disponible en Mednet: http://mednet.who.int/

AMENDMENTS TO PREVIOUS LISTS
MODIFICATIONS APPORTÉES AUX LISTES ANTÉRIEURES
MODIFICACIONES A LAS LISTAS ANTERIORES

Recommended International Nonproprietary Names (Rec. INN): List 21
Dénominations communes internationales recommandées (DCI Rec.): Liste 21
Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 21
(WHO Drug Information, Vol. 35, No. 5, 1981)

	delete/supprimer/suprímase	*insert/insérer/insertése*
p. 4	docusatum natricum	natrii docusas

Recommended International Nonproprietary Names (Rec. INN): List 54
Dénominations communes internationales recommandées (DCI Rec.): Liste 54
Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 54
(WHO Drug Information, Vol. 19, No. 3, 2005)

	suprímase	*insertése*
p. 253	epoetina zeta	epoetina dseta

Procedure and Guiding Principles / Procédure et Directives / Procedimientos y principios generales

The text of the *Procedures for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances* and *General Principles for Guidance in Devising International Nonproprietary Names for Pharmaceutical Substances* will be reproduced in proposed INN lists only.

Les textes de la *Procédure à suivre en vue du choix de dénominations communes internationales recommandées pour les substances pharmaceutiques* et des *Directives générales pour la formation de dénominations communes internationales applicables aux substances pharmaceutiques* seront publiés seulement dans les listes des DCI proposées.

El texto de los *Procedimientos de selección de denominaciones comunes internacionales recomendadas para las sustancias farmacéuticas* y de los *Principios generales de orientación para formar denominaciones comunes internacionales para sustancias farmacéuticas* aparece solamente en las listas de DCI propuestas.